Skip to main content

FDA Approvals

Cosela First CDK4/6 Inhibitor FDA Approved to Reduce Chemotherapy-Induced Myelosuppression

Vyxeos Now Indicated for Treatment of Pediatric Patients with AML

FDA Approvals, Lymphoma

FDA Approved Ukoniq, New Targeted Therapy, for Marginal-Zone and Follicular Lymphoma

FDA Approvals, Lymphoma

FDA Approved Breyanzi, Novel CAR T-Cell Therapy, for Large B-Cell Lymphoma

FDA Approvals, Multiple Myeloma, Oncology

FDA Approved Pepaxto for Relapsed or Refractory Multiple Myeloma

FDA Approvals, Multiple Myeloma, Oncology

FDA Approved Abecma, First CAR T-Cell Therapy for Multiple Myeloma

Novel Target: RARA Agonist plus Azacitidine Active in Relapsed or Refractory Acute Myeloid Leukemia

Phoebe Starr

Magrolimab, First CD47 Antibody, Shows Promise in Combination with Azacitidine in Unfit Patients with Acute Myeloid Leukemia

Wayne Kuznar

Oral Vodobatinib Elicits Durable Responses in Heavily Pretreated Patients with Chronic Myeloid Leukemia

Chase Doyle

FDA Approvals, Multiple Myeloma, Oncology

Xpovio Approved for Patients with Relapsed or Refractory Multiple Myeloma

Page 13 of 53
Results 121 - 130 of 524